The U.S. government is actively working to establish a domestic supply of molybdenum-99 (Mo-99), a crucial radioisotope used in over 75% of medical nuclear imaging exams, to reduce reliance on foreign sources and enhance the stability of the medical imaging supply chain. Currently, the U.S. obtains all of its Mo-99 from international reactors, which has proven vulnerable during periods of maintenance and repairs on key facilities. Cathy Cutler, President of the Society of Nuclear Medicine and Molecular Imaging, emphasized the critical need for a reliable domestic supply, especially for oncology and cardiology imaging. Recent developments include Shine Technologies receiving $32 million in federal funding to improve Mo-99 production capabilities, and the University of Missouri's plans to build a new reactor to support isotope production, though this will take several years. Economic challenges have hindered progress, with companies like NorthStar Medical Radioisotopes halting production due to competition from subsidized international reactors. The situation is compounded by national security concerns linked to the history of using highly enriched uranium (HEU) in Mo-99 production, leading to a transition to low-enriched uranium (LEU) targets. Continued Congressional support is deemed essential for future advancements in the domestic Mo-99 supply chain. In related news, a total of 16 cardiology practices from 12 states settled with the Department of Justice over allegations of overbilling Medicare for imaging agents. Additionally, an international group of specialists noted the increased use of coronary CT angiography (CCTA) for diagnosing coronary artery disease, highlighting its potential to enhance imaging workflows and patient care.
Wed, 18 Dec 2024 20:41:52 GMT | Health Imaging